Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker.

LaPar DJ, Burdick MD, Emaminia A, Harris DA, Strieter BA, Liu L, Robbins M, Kron IL, Strieter RM, Lau CL.

Ann Thorac Surg. 2011 Aug;92(2):470-7; discussion 477. doi: 10.1016/j.athoracsur.2011.04.065.

2.

Altered progenitor cell and cytokine profiles in bronchiolitis obliterans syndrome.

Gilpin SE, Lung KC, Sato M, Singer LG, Keshavjee S, Waddell TK.

J Heart Lung Transplant. 2012 Feb;31(2):222-8. doi: 10.1016/j.healun.2011.11.012.

PMID:
22305385
3.

Increased circulating fibrocytes in asthma with chronic airflow obstruction.

Wang CH, Huang CD, Lin HC, Lee KY, Lin SM, Liu CY, Huang KH, Ko YS, Chung KF, Kuo HP.

Am J Respir Crit Care Med. 2008 Sep 15;178(6):583-91. doi: 10.1164/rccm.200710-1557OC. Epub 2008 Jun 26.

PMID:
18583572
4.

Inhibiting CXCL12 blocks fibrocyte migration and differentiation and attenuates bronchiolitis obliterans in a murine heterotopic tracheal transplant model.

Harris DA, Zhao Y, LaPar DJ, Emaminia A, Steidle JF, Stoler M, Linden J, Kron IL, Lau CL.

J Thorac Cardiovasc Surg. 2013 Mar;145(3):854-61. doi: 10.1016/j.jtcvs.2012.03.079. Epub 2012 May 22.

5.

Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group.

Sundaresan S, Trulock EP, Mohanakumar T, Cooper JD, Patterson GA.

Ann Thorac Surg. 1995 Nov;60(5):1341-6; discussion 1346-7.

PMID:
8526624
6.

Reliability of diagnostic criteria for bronchiolitis obliterans syndrome after lung transplantation: a survey.

Kapila A, Baz MA, Valentine VG, Bhorade SM; AIRSAC investigators.

J Heart Lung Transplant. 2015 Jan;34(1):65-74. doi: 10.1016/j.healun.2014.09.029. Epub 2014 Oct 7.

PMID:
25447585
7.

Fibrocytes are associated with vascular and parenchymal remodelling in patients with obliterative bronchiolitis.

Andersson-Sjöland A, Erjefält JS, Bjermer L, Eriksson L, Westergren-Thorsson G.

Respir Res. 2009 Oct 30;10:103. doi: 10.1186/1465-9921-10-103.

8.

Single lung transplantation for chronic obstructive pulmonary disease: pulmonary function and impact of bronchiolitis obliterans syndrome.

Bjørtuft O, Geiran OR, Fjeld J, Skovlund E, Johansen B, Boe J.

Respir Med. 1996 Oct;90(9):553-9.

9.

Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients.

Lama VN, Murray S, Lonigro RJ, Toews GB, Chang A, Lau C, Flint A, Chan KM, Martinez FJ.

Am J Respir Crit Care Med. 2007 Jun 1;175(11):1192-8. Epub 2007 Mar 8.

10.

Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation.

Ohshimo S, Bonella F, Sommerwerck U, Teschler H, Kamler M, Jakob HG, Kohno N, Guzman J, Costabel U.

J Heart Lung Transplant. 2011 Dec;30(12):1374-80. doi: 10.1016/j.healun.2011.07.010. Epub 2011 Aug 25.

PMID:
21871820
11.

The impact of cytolytic therapy on bronchiolitis obliterans syndrome.

Date H, Lynch JP, Sundaresan S, Patterson GA, Trulock EP.

J Heart Lung Transplant. 1998 Sep;17(9):869-75.

PMID:
9773858
12.

The number of FoxP3+ cells in transbronchial lung allograft biopsies does not predict bronchiolitis obliterans syndrome within the first five years after transplantation.

Krustrup D, Iversen M, Martinussen T, Schultz HH, Andersen CB.

Clin Transplant. 2015 Mar;29(3):179-84. doi: 10.1111/ctr.12502. Epub 2015 Mar 9.

PMID:
25533723
13.

Resident tissue-specific mesenchymal progenitor cells contribute to fibrogenesis in human lung allografts.

Walker N, Badri L, Wettlaufer S, Flint A, Sajjan U, Krebsbach PH, Keshamouni VG, Peters-Golden M, Lama VN.

Am J Pathol. 2011 Jun;178(6):2461-9. doi: 10.1016/j.ajpath.2011.01.058.

14.

Soluble CD30 measured after lung transplantation does not predict bronchiolitis obliterans syndrome in a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen.

Kwakkel-van Erp JM, Otten HG, Paantjens AW, van Kessel DA, van Ginkel WG, van den Bosch JM, van de Graaf EA.

J Heart Lung Transplant. 2008 Oct;27(10):1172-5. doi: 10.1016/j.healun.2008.06.007.

PMID:
18926413
15.

Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis.

Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, O'Byrne PM, Strieter RM, Kolb M.

Am J Respir Crit Care Med. 2009 Apr 1;179(7):588-94. doi: 10.1164/rccm.200810-1534OC. Epub 2009 Jan 16.

PMID:
19151190
16.

Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients.

Neurohr C, Huppmann P, Samweber B, Leuschner S, Zimmermann G, Leuchte H, Baumgartner R, Hatz R, Frey L, Ueberfuhr P, Bittmann I, Behr J; Munich Lung Transplant Group.

J Heart Lung Transplant. 2009 May;28(5):468-74. doi: 10.1016/j.healun.2009.01.014. Epub 2009 Mar 14.

PMID:
19416775
17.
18.

What are the best pulmonary function test parameters for early detection of post-lung transplant bronchiolitis obliterans syndrome in children?

Sritippayawan S, Keens TG, Horn MV, Starnes VA, Woo MS.

Pediatr Transplant. 2003 Jun;7(3):200-3.

PMID:
12756044
19.

Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant.

Riise GC, Andersson BA, Kjellström C, Martensson G, Nilsson FN, Ryd W, Scherstén H.

Eur Respir J. 1999 Nov;14(5):1123-30.

20.

Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome.

Palmer SM, Davis RD, Hadjiliadis D, Hertz MI, Howell DN, Ward FE, Savik K, Reinsmoen NL.

Transplantation. 2002 Sep 27;74(6):799-804.

PMID:
12364858
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk